Drug Search Results
More Filters [+]

SAIL Biomed CD19 CAR-T

Alternative Names: SAIL Biomed CD19 CAR-T
Latest Update: None
Latest Update Note: None

Product Description

mRNA therapeutic compositions including one or more polynucleotides encoding one or more tumor antigenic, immunogenic, or signaling polypeptides, formulated within a lipid reconstructed plant messenger packs (LPMPs) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making a mRNA therapeutic composition, comprising reconstituting a film comprising purified PMP lipids in the presence of an ionizable lipid to produce a LPMP comprising the ionizable lipid, and loading into the LPMPs with one or more polynucleotides encoding one or more tumor antigenic or immunogenic polypeptides. (Sourced from: https://patents.google.com/patent/CA3241014A1/en?q=(cd19)&assignee=sail+biomedicines&before=publication:20240814&after=publication:20220101)

Mechanisms of Action: CAR-T,CD19

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sail Biomedicines
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SAIL Biomed CD19 CAR-T

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title